Predictors of response to immunotherapy
death, tumour
TUMOUR
Fifteen (94%) in group 1 and 31 (97%) in group 2 had an evaluable TMB; 7 and 3 patients in group 1 and 2, respectively, had a high TMB of ≥10 mutations/megabase. In group 1 median PFS was 4.3 months for high, compared with 2.9 months for low TMB (HR 0.35, 95% CI 0.10–1.23; log-rank PD-L1 expression was available for 13 patients (81%) in group 1 and 29 patients (91%) in group 2. Median tumour PD-L1 expression was 1 and 0% for groups 1 and 2, respectively, with 44 and 41% meeting the PD-L1 expression cut-off of ≥1%. PD-L1 expression by group, or across study participants did not correlate with PFS (HR 1.11, 95% CI 0.58–2.14, Exploratory analysis using an NLR threshold of 4 demonstrated that patients across both groups with an NLR ≥ 4 demonstrated a shorter OS (median 10.1 months) compared with NLR < 4 (median 15.3 months), HR for death 1.64 (95% CI 0.85–3.18; 